Five adjuvant breast cancer trials have clearly demonstrated the benefit of trastuzumab in reducing the recurrence rate and mortality in patients with aggressive HER2-positive disease. The controversies and challenges relating to the use of trastuzumab in the adjuvant setting, such as the optimal timing and duration, its use with taxanes and radiotherapy, its role in small node-negative tumors and cost-effectiveness are discussed.
- Phuong Dinh
- Evandro de Azambuja
- Martine J Piccart-Gebhart
